Duke Cancer Institute, Duke Medicine, Durham, NC 27710, USA.
Cone Health Cancer Center, Greensboro, NC 27403, USA.
Future Oncol. 2024;20(21):1515-1530. doi: 10.2217/fon-2023-0513. Epub 2024 Apr 8.
Side effects from chemotherapy-induced myelosuppression can negatively affect patients' quality of life (QoL). Neutropenia increases infection risk, and anemia frequently results in debilitating fatigue. Additionally, the bleeding risk associated with thrombocytopenia can lead to fear and anxiety. However, traditional interventions for myelosuppression fall short of the ideal. Granulocyte colony-stimulating factors reduce the risk of severe neutropenia but commonly lead to bone pain. Erythropoiesis-stimulating agents are not always effective and may cause thromboembolic events, while transfusions to correct anemia/thrombocytopenia are associated with transfusion reactions and volume overload. Trilaciclib, which is approved for reducing myelosuppression in patients with extensive-stage small cell lung cancer, together with several investigational agents in development for managing myelosuppression have the potential to improve QoL for patients on chemotherapy.
化疗引起的骨髓抑制的副作用可能会对患者的生活质量（QoL）产生负面影响。中性粒细胞减少症会增加感染风险，而贫血常导致使人虚弱的疲劳。此外，血小板减少症相关的出血风险会导致恐惧和焦虑。然而，骨髓抑制的传统干预措施并不理想。粒细胞集落刺激因子可降低严重中性粒细胞减少症的风险，但通常会导致骨痛。促红细胞生成素刺激剂并不总是有效，可能会引起血栓栓塞事件，而纠正贫血/血小板减少症的输血则与输血反应和血容量过多有关。 Trilaciclib 已被批准用于减少广泛期小细胞肺癌患者的骨髓抑制，与几种正在开发用于治疗骨髓抑制的研究性药物一起，有可能改善接受化疗的患者的生活质量。
